Literature DB >> 32893333

The Role of the Renin-Angiotensin-Aldosterone System in Preeclampsia: a Review.

Premjith Gathiram1, Jagidesa Moodley2,3.   

Abstract

PURPOSE OF REVIEW: Preeclampsia (PE) is a complex human pregnancy-specific condition and is clinically characterized by new onset hypertension and proteinuria in the second half of pregnancy. The precise etiology of PE is unknown, but much of the pathophysiology has been elucidated, and it is accepted that the disorder is multifactorial in nature. Historically, because of the presence of proteinuria, the role of the renin-angiotensin-aldosterone system (RAAS) has been considered in the etiology of PE. However, the results of studies (including maternal circulatory angiotensin II, urinary angiotensinogen, plasma renin and prorenin, AT1 receptor antibodies, and gene polymorphisms) on the role of the RAAS in the etiology of PE have proved controversial. The purpose of this narrative review was to evaluate the contemporary literature on the RAAS and its role in the pathophysiology of pregnancy. RECENT
FINDINGS: The current review shows that although the RAAS has a role in the development of normal pregnancy, it does not have a significant role in the pathophysiology of PE except for the AT1-AA components. Despite many researchers having measured increases in s[P}RR and [P]RR, this may be independent of the RAAS. Our view is in keeping with contemporary thinking that the placenta rather than the RAAS plays a central role in elaborating pro-inflammatory factors (antiangiogenic and angiogenic) into the maternal circulation resulting in widespread endothelial dysfunction in all organ systems including the renal system.

Entities:  

Keywords:  Aldosterone; Angiotensin; Preeclampsia; Prorenin; Renin

Year:  2020        PMID: 32893333     DOI: 10.1007/s11906-020-01098-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  7 in total

1.  Midgestation Leptin Infusion Induces Characteristics of Clinical Preeclampsia in Mice, Which Is Ablated by Endothelial Mineralocorticoid Receptor Deletion.

Authors:  Jessica L Faulkner; Derrian Wright; Galina Antonova; Iris Z Jaffe; Simone Kennard; Eric J Belin de Chantemèle
Journal:  Hypertension       Date:  2022-05-05       Impact factor: 9.897

2.  The Novel Peptide AEDPPE Alleviates Trophoblast Cell Dysfunction Associated With Preeclampsia by Regulating the NF-κB Signaling Pathway.

Authors:  Yixiao Wang; Yan Cao; Xiaohong Ji; Ting Li; Lu Xue; Chanjuan Li; Ruizhe Jia; Hongjuan Ding
Journal:  Front Cardiovasc Med       Date:  2021-12-17

Review 3.  Could Vitamin D Be Effective in Prevention of Preeclampsia?

Authors:  Elżbieta Poniedziałek-Czajkowska; Radzisław Mierzyński
Journal:  Nutrients       Date:  2021-10-28       Impact factor: 5.717

4.  Elevated mid-pregnancy plasma levels of angiotensin-converting enzyme 2 in women prior to the development of preeclampsia.

Authors:  Katja Junus; Inger Björk Ragnarsdóttir; Paliz Nordlöf Callbo; Lina Bergman; Susanne Lager; Anna-Karin Wikström
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

5.  Urinary Angiotensinogen-Melatonin Ratio in Gestational Diabetes and Preeclampsia.

Authors:  Gabriela Ribeiro Valias; Patricia Rodrigues Lourenço Gomes; Fernanda G Amaral; Saif Alnuaimi; Daniela Monteiro; Siobhán O'Sullivan; Renato Zangaro; José Cipolla-Neto; Juan Acuna; Ovidiu Constantin Baltatu; Luciana Aparecida Campos
Journal:  Front Mol Biosci       Date:  2022-03-02

6.  Downregulation of cathepsin C alleviates endothelial cell dysfunction by suppressing p38 MAPK/NF-κB pathway in preeclampsia.

Authors:  Fan Lu; Han Gong; Houkang Lei; Juan Li
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 7.  Insight into the Key Points of Preeclampsia Pathophysiology: Uterine Artery Remodeling and the Role of MicroRNAs.

Authors:  Katarzyna Pankiewicz; Anna Fijałkowska; Tadeusz Issat; Tomasz M Maciejewski
Journal:  Int J Mol Sci       Date:  2021-03-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.